SEC Form 4 · accession 0001179110-18-004061
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Ferra Jr.
Officer — Chief Financial Officer
Period of report
Mar 12, 2018
Accepted (ET)
Mar 12, 2018 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.32 | Mar 12, 2018 | A | 150,000 | A | — | Mar 11, 2028 | Common Stock | 150,000 | 150,000 | D |
| Stock Option (right to buy)F2 | $12.32 | Mar 12, 2018 | A | 50,000 | A | — | Mar 11, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This option becomes exercisable as to 25% of the shares underlying the award on March 12, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until March 12, 2022, subject to Mr. Ferra's continued service as an employee through each applicable vesting date.
- F2This option vests upon the achievement of performance-based criteria, and in any event will vest in full on March 12, 2024.